In a world of increasing fragmentation and polarisation, the 78th World Health Assembly, starting Monday, will present itself ...

The global drug delivery technology market is on a transformative trajectory, projected to soar from USD 52.1 billion in 2025 to an astounding USD 136.7 billion by 2035. This reflects a robust CAGR of ...

Late-stage trial data suggest that a new COVID-flu vaccine offers good protection against both infections, but experts expect ...

China on Sunday announced anti-dumping duties as high as 74.9% on imports of POM copolymers, a type of engineering plastic, ...

This vaccine did previously have emergency approval by the FDA for use but can now be marketed in the U.S. for use, the ...

The U.S. Food and Drug Administration (FDA) has granted full approval to Novavax's COVID-19 vaccine, but only for certain people.

Novavax (NVAX) shares climbed more than 17% premarket on Monday after the long-delayed approval of its COVID-19 vaccine from ...

Novavax received Food and Drug Administration approval for its new, protein-based COVID-19 vaccine, and shares jumped 25% at the opening bell Monday.

Novavax had expected full approval for broader use by April 1, after the FDA reviewed data from a 30,000-person clinical ...

The U.S. Food and Drug Administration approved Novavax’s Covid-19 vaccine, but limited its use to older adults and people over the age of 12 with conditions that put them at risk due to the illness.

The U.S. Food and Drug Administration approved Novavax's COVIDd-19 vaccine with age restrictions after a six-week delay.

Nuvaxovid had been available under emergency use authorization but the full approval may allow it to better compete with ...